Mounjaro Soars: India's Best-Selling Obesity Drug Hits ₹100 Crore in Sales

Eli Lillys Mounjaro emerges as Indias top-selling obesity drug in October, with ₹100 crore in sales, reflecting the increasing need for effective diabetes and obesity treatments.

In October, Mounjaro achieved sales of ₹100 crore ($11.38 million), becoming Indias leading drug by value, according to research firm Pharmarack.
The rise of Mounjaro highlights the urgent demand for anti-obesity medication in India, where approximately 101 million individuals suffer from diabetes.
Mounjaro offers a significant alternative to other weight loss treatments, such as Semaglutide, which is also used to manage blood sugar level in diabetes patients.

Why It Matters

The success of Mounjaro underscores the critical need for effective solutions to combat obesity and diabetes in India, reflecting broader global health trends. With rising obesity rates, such medications could play a vital role in improving public health outcomes.